吉西他滨肝动脉灌注联合卡培他滨治疗耐药乳腺癌肝转移  

Gemcitabine arterial joint drug capecitabine treatment for drug-resistant breast cancer liver metastasis

作　　者：王勇 卢慧民 WANG Yong;LU Hui-min(Puyang the Fifth People＇s Hospital,Puyang,Henan 457000,China)

机构地区：[1]濮阳市第五人民医院肿瘤科,河南濮阳457000

出　　处：《医药论坛杂志》2018年第8期47-48,53,共3页Journal of Medical Forum

摘　　要：目的观察吉西他滨肝固有动脉灌注联合卡培他滨口服治疗一线化疗后耐药乳腺癌肝转移疗效及安全性。方法对95例乳腺癌肝转移者,分治疗组48例,对照组47例。治疗组乳腺癌肝转移者行经肝固有动脉灌注吉西他滨,对照组吉西他滨静脉应用,两组卡培他滨均分2次/d,口服,2个周期后评价疗效。结果治疗组有效率(CR+PR)56.3%。对症组有效率(CR+PR)34.4%。两组比较差异有统计学意义(P<0.05),两组患者均无治疗相关性死亡,主要不良反应为血液学及胃肠道反应及手足综合征,患者均可耐受。结论吉西他滨肝固有动脉灌注联合卡培他滨口服治疗乳腺癌肝转移对一线化疗药物耐药者,具有一定的肿瘤客观缓解率,临床受益反应率高,不良反应能耐受。Objective To observe the efficacy and safety of chemotherapy for the hepatic metastasis of breast cancer after first-line chemotherapy with the combined capecitabine of gemcitabine. Methods In 95 cases of liver metastasis of breast cancer,48 cases were divided into treatment group and 47 cases in control group. In the treatment group,the hepatic metastasis of breast cancer was treated with hepatic arterial perfusion in gemcitabine,and in the control group,gemcitabine vein was applied in the control group,and the two groups of capecitabine were divided into two oral cycles,and the efficacy was evaluated after 2 cycles. Results The effective treatment group（ CR ＋ PR） was 56. 3%. The effective rate（ CR ＋ PR） was 34. 4%. There were significant differences between the two groups（ P 〈 0. 05）. The patients in both groups had no treatment related death,and the main adverse reactions were hematology and gastrointestinal reactions and hand and hand syndrome,and the patients were all tolerated. Conclusion Gemcitabine arterial perfusion combined capecitabine oral treatment for liver metastasis of breast cancer drug resistance to first-line chemotherapy drugs,have certain objective tumor response rate,high clinical benefit response rate,adverse reaction is tolerated.

关 键 词：吉西他滨 卡培他滨 乳腺癌 肝转移 动脉给药 

分 类 号：R737.9[医药卫生—肿瘤]